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In the Introduction, the sentence ‘‘The IDF
guidelines recommend starting with a long-
acting basal insulin analog, with pre-mixed
insulin for those with higher HbA1C’’ should
read:
‘‘The IDF guidelines recommend starting with a
long-acting basal insulin, and suggest starting
with pre-mixed insulins for those with a higher
starting HbA1C.’’
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